ESTUDIO MULTICÉNTRICO, NO ALEATORIZADO Y ABIERTO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE IBRUTINIB SEGUIDO POR CONSOLIDACIÓN CON OFATUMUMAB, EN PACIENTES CON LEUCEMIA LINFOCÍTICA CRÓNICA (LLC) O LINFOMA LINFOCÍTICO DE CÉLULAS PEQUEÑAS (LLCP) SIN TRATAMIENTO PREVIO.

Datos básicos

Código:
GELLC-7
Protocolo:
GELLC-7
EUDRACT:
2016-004937-26
NCT:
Centro:
HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Dotación:
Año de incio:
2017
Año de finalización:
2023
ENSAYO CLÍNICO INTERNACIONAL

Documentos

  • No hay documentos

Participantes

Grupos

Financiadores - Promotores

FUNDACION PETHEMA

Resultados del Ensayo Clínico


2019 SEFH National Survey: service portfolio, care activities, education and research in Spain's hospital pharmacy departments.

Pérez-Encinas M; (...); Calleja-Hernández MÁ

Article. 10.7399/fh.11611. 2021

  • Open Access.

A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients.

Lozano ML; (...); Vicente V

Article. 10.1016/j.bcmd.2020.102505. 2021

  • Open Access.

A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain

Zozaya, Neboa; (...); Hidalgo-Vega, Alvaro

Article. 10.33393/grhta.2022.2333. 2022

  • Open Access.

A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.

Zozaya, Neboa; (...); Verde, Luis

Article. 10.1017/S0266462322000459. 2022

  • Open Access.

A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study.

de Andrés-Nogales F; (...); Martínez-Olmos J

Article. 10.1007/s41669-020-00201-2. 2020

  • Open Access.

A MULTI-STAKEHOLDER MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD STUDY.

Casado, MA; (...); Grp MULTIDEX-EMD

Meeting Abstract. 10.1016/j.jval.2018.09.2545. 2018

  • Open Access.

A new definition and refocus of pharmaceutical care: the Barbate Document

Morillo-Verdugo R; (...); Poveda-Andrés JL

Article. 10.7399/fh.11389. 2020

  • Open Access.

A randomized phase II study comparing consolidation with a single dose of Y-90 ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results

Lopez-Guillermo, Armando; (...); Tomas, Jose Francisco

Article. 10.1080/10428194.2021.1971216. 2021


A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

Encinas, Cristina; (...); Martinez-Lopez, Joaquin

Article. 10.1038/s41408-022-00652-2. 2022

  • Open Access.

Accuracy and prognostic impact of FDG PET/CT and biopsyin bone marrow assessment of follicular lymphomaat diagnosis: A Nation-Wide cohort study.

Rodenas-Quinonero, Isabel; (...); Ortuno, Francisco Jose

Article. 10.1002/cam4.5424. 2022

  • Open Access.

Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin's lymphoma: report on three cases and literature review

Romero, S; (...); Sanz, J

Review. 10.1177/20406207211038181. 2021

  • Open Access.

Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study.

Ballesta-López O; (...); Poveda-Andrés JL

Article. 10.1177/1078155220915953. 2020


Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice

Stadtmauer, Edward A.; (...); ZOE-SCT Study Grp Collaborators

Article. 10.1080/21645515.2021.1953346. 2021

  • Open Access.

Analysing criteria for price and reimbursement of orphan drugs in Spain.

Badia, X; (...); Tort, M

Article. 10.7399/fh.11147. 2019

  • Open Access.

Analysis of chemical contamination by hazardous drugs with BD HD Check(R) system in a tertiary hospital

Valero García S; (...); Poveda Andrés JL

Article. 10.1177/10781552211038518. 2021


ANALYSIS OF PROGRESSION-FREE SURVIVAL OF AND GLOBAL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA OLDER THAN 65 YEARS CANDIDATES FOR AUTOLOGOUS PERIPHERAL BLOOD TRANSPLANTATION NON-CANDIDATES

Cejalvo, MJ; (...); De la Rubia, J

Meeting Abstract. 2017

  • Open Access.

Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype

Ibanez, M; (...); Cervera, J

Article. 10.1038/s41598-020-61589-9. 2020

  • Open Access.

ANALYSIS OF THE PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN ELDERLY PATIENTS (65 YEARS OLD) WITH MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION.

Cejalvo, MJ; (...); De la Rubia J

Meeting Abstract. 2018

  • Open Access.

Antimicrobial stewardship programme implementation in a medical ward

Ruiz, J; (...); Poveda, JL

Article. 2018


Antimicrobial stewardship programme in critical care medicine: A prospective interventional study

Ruiz, J; (...); Catellanos, A

Article. 10.1016/j.medin.2017.07.002. 2018


Autologous stem cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study.

García-Sancho AM; (...); Caballero D

Article. 10.3324/haematol.2021.279426. 2022

  • Open Access.

Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure

Jiménez-Ubieto A; (...); Lahuerta JJ

Article. 10.1016/j.bbmt.2017.05.021. 2017

  • Open Access.

Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment

Jimenez-Ubieto, A; (...); GELTAMO Grp Espanol Linfomas Tr

Article. 10.1002/hon.2553. 2018


Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy.

Jiménez-Ubieto A; (...); GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Stu

Article. 10.1016/j.hemonc.2019.06.001. 2019

  • Open Access.

Autologous Stem Cell Transplantation may potentially abrogate the negative prognostic effect of early relapse after chemo or inmunochemotherapy in Follicular Lymphoma

Ubieto, AJ; (...); Lahuerta, JJ

Meeting Abstract. 2018


AUTONOMOUS TRANSPLANTATION CAN MITIGATE THE ADVERSE PROGNOSIS OF THE EARLY RELAPSE AFTER CHEMO OR IMMUNOCHEMOTHERAPY INDUCTION IN FOLLICULAR LYMPHOMA

Ubieto, AJ; (...); Lahuerta, J. J.

Meeting Abstract. 2017

  • Open Access.

Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.

Iglesias Gómez R; (...); Poveda Andrés JL

Article. 10.1136/ejhpharm-2021-002741. 2021

  • Open Access.

Bayesian pharmacokinetic individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A

Megias-Vericat, JE; (...); Bonanad, S

Meeting Abstract. 2018


Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A

Megias-Vericat, JE; (...); Poveda, JL

Article. 10.1016/j.thromres.2018.12.027. 2019


Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group

Redondo, AM; (...); GEL-TAMO

Article. 10.1111/bjh.15713. 2019


Bendamustine plus rituximab in untreated chronic lymphocytic leukemia patients. The MDA-CLL-2015-02 study

De La Fuente, A; (...); Baltasar, P

Meeting Abstract. 2017


Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.

Fernandez Rivera C; (...); Hernandez D

Article. 10.1111/ctr.14550. 2022

  • Open Access.

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplantation in multiple myeloma.

Rosiñol L; (...); Bladé J

Article. 10.1182/blood.2019000241. 2019

  • Open Access.

Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.

Balaguer-Rosello, Aitana; (...); Sanz, Jaime

Article. 10.1016/j.jtct.2020.12.019. 2021

  • Open Access.

Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients

Megias-Vericat, JE; (...); Poveda, JL

Article. 10.1016/j.thromres.2021.07.009. 2021


Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country.

Muntañola A; (...); Bosch F

Letter. 10.1186/s40164-020-00195-x. 2020

  • Open Access.

Clinical Characteristics and Transfusion Management of Patients Diagnosed of Multiple Myeloma Receiving Daratumumab: Experience of a Single Centre

Arnao, M; (...); Sanz, G

Meeting Abstract. 10.1016/j.clml.2019.09.254. 2019


Clinical pharmacy services: from cost-effectiveness analysis to a productivity indicators model

Nogueras, A; (...); Calleja, MA

Letter. 10.1136/ejhpharm-2019-001905. 2019

  • Open Access.

Collaborative model of home delivery program in haemophilia through an association of patients

Megias-Vericat, JE; (...); Bonanad, S

Meeting Abstract. 2018


COMPARATIVE STUDY OF THE CLINICAL-BIOLOGICAL CHARACTERISTICS TO THE DIAGNOSIS AND RELAPSE IN PATIENTS WITH MULTIPLE MYELOMA

Valenzuela, AV; (...); Ramos, IJ

Meeting Abstract. 2018

  • Open Access.

Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo

Megias-Vericat, JE; (...); Poveda, JL

Meeting Abstract. 2020


Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation

Solves, P; (...); Sanz, GF

Article. 10.1111/ejh.13270. 2019


Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano JB; (...); Soto-Ortega I

Article. 10.1016/j.farma.2023.01.003. 2023

  • Open Access.

Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada

Article. 10.1016/j.farma.2023.04.002. 2023


Copper deficiency: a cause of misdiagnosis of myelodysplastic syndrome

Villalba, A; (...); Senent, L

Letter. 10.1007/s00277-018-3334-5. 2018


COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA

Gironella, M.; (...); Oyaguez, I

Meeting Abstract. 2019

  • Open Access.

Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.

Poveda JL; (...); Torres C

Article. 10.1080/14737167.2019.1635014. 2020

  • Open Access.

COST-EFFECTIVENESS OF CLADRIBINE TABLETS AND FINGOLIMOD IN THE TREATMENT OF REMITTING MULTIPLE SCLEROSIS WITH HIGH DISEASE ACTIVITY IN SPAIN

Trillo, JL; (...); Torres, C

Meeting Abstract. 10.1016/j.jval.2018.09.2029. 2018

  • Open Access.

COSTS OF THE MANAGEMENT OF HEMOPHILIA A WITH INHIBITORS IN SPAIN

Bonanad, S; (...); Gonzalez-Dominguez, A

Meeting Abstract. 2020


Costs of the management of hemophilia A with inhibitors in Spain

Bonanad, S; (...); Gonzalez-Dominguez, A

Article. 10.33393/grhta.2021.2234. 2021

  • Open Access.

Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia

Casado, LF; (...); Castro, A

Article. 10.1111/ejh.13007. 2018

  • Open Access.

COST-UTILITY OF IDELALISIB IN COMBINATION WITH RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

Casado, LF; (...); Castro-Gomez, A

Meeting Abstract. 10.1016/j.jval.2017.08.898. 2017


CRITICAL REVIEW OF THE DOUBLE NEGATIVITY IN THE SERUM AND URINE IMMUNOFIXATION (IF) TO ESTABLISH THE CATEGORY OF COMPLETE REMISSION IN MULTIPLE MYELOMA (MM)

Anglada, LL; (...); Lahuerta, J. J.

Meeting Abstract. 2017

  • Open Access.

Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis

Megias-Vericat, JE; (...); Poveda, JL

Letter. 10.1111/hae.13733. 2019


Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products

Eduardo Megias, Juan; (...); Iorio, Alfonso

Meeting Abstract. 10.1182/blood-2019-127946. 2019

  • Open Access.

Cytokine response as a biomarker for early diagnosis and outcome prediction of stem cell transplant recipients and acute leukemia patients with invasive aspergillosis.

Puerta-Alcalde, Pedro; (...); Garcia-Vidal, Carolina

Article. 10.1093/mmy/myac038. 2022


Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib.

Solano de la Asuncion, Carlos; (...); Navarro, David

Letter. 10.1111/bjh.17732. 2021

  • Open Access.

Cytotoxic Natural Killer Subpopulations as a Prognostic Factor of Malignant Pleural Effusion

Lara, SH; (...); Suarez-Varela, MM

Article. 10.1007/s00408-018-0186-7. 2019


Chronic liver disease-associated severe thrombocytopenia in Spain: Results from a retrospective study using machine learning and natural language processing.

Calleja-Panero, Jose Luis; (...); Gonzalez Calvo, Jose

Article. 10.1016/j.gastrohep.2023.05.010. 2023

  • Open Access.

Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review

Megias-Vericat, JE; (...); Montesinos, P

Review. 10.1080/17512433.2019.1573668. 2019


Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (vol 11, 16867, 2021)

Lozano, Maria L.; (...); Vicente, Vicente

Article. 10.1038/s41598-021-95732-x. 2021

  • Open Access.

Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia.

Lozano ML; (...); Vicente V

Article. 10.1038/s41598-019-53209-y. 2019

  • Open Access.

Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project

Blade, J; (...); Lizan, L

Article. 10.1136/bmjopen-2017-018850. 2018

  • Open Access.

Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.

Salinas P; (...); Escaned J

Article. 10.1016/j.carrev.2021.11.015. 2021


Design and Validation of a Custom Next-Generation Sequencing Panel in Pediatric Acute Lymphoblastic Leukemia.

Gil, Jose Vicente; (...); Barragan, Eva

Article. 10.3390/ijms24054440. 2023

  • Open Access.

DETERMINATION OF THE CHALLENGES AND OPPORTUNITIES ASSOCIATED WITH PLATELET TRANSFUSION IN THE MANAGEMENT OF PATIENTS WITH SEVERE THROMBOCYTOPENIA ASSOCIATED WITH CHRONIC LIVER DISEASE

Jarque, Ramos, I; (...); Shepherd, Moreno J.

Meeting Abstract. 2020

  • Open Access.

DETERMINING THE EPIDEMIOLOGY, PATIENT FLOW, TREATMENT AND UNMET NEEDS OF PATIENTS WITH CHRONIC LIVER DISEASE-ASSOCIATED SEVERE THROMBOCYTOPENIA UNDERGOING INVASIVE PROCEDURES IN SPAIN

Andrade, R.; (...); Shepherd, J.

Meeting Abstract. 2019


Determining the value contribution of emicizumab (Hemlibra (R)) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis

Alvarez-Roman, MT; (...); Badia, X

Article. 10.1177/2284240319880534. 2019

  • Open Access.

DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

Alvarez, E.; (...); Badia, F. J.

Meeting Abstract. 2019


DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN

Poveda, J. L.; (...); Vitoria, I

Meeting Abstract. 2019


Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain

Badia, X; (...); Poved, JL

Article. 10.1080/21678707.2019.1652163. 2019


Do Guidelines Influence Diagnostic and Therapeutic Practice in Immune Thrombocytopenia? Results of a Multicenter Retrospective Study

Luisa Lozano, Maria; (...); Vicente Garcia, Vicente

Meeting Abstract. 10.1182/blood-2019-125557. 2019

  • Open Access.

Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan

Ribera, E; (...); Hernandez-Novoa, B

Article. 10.1016/j.eimc.2016.11.015. 2018


Efecto de la adición de fortificantes y de módulo de proteínas en la osmolalidad de la leche materna donada.

Torres Martínez E; (...); Vento M

Article. 10.1016/j.anpedi.2020.03.009. 2020

  • Open Access.

EFFECT OF PREGNANCY IN THE CLINICAL COURSE OF PREGNANT WOMEN WITH PTI AND THEIR OFFSPRING. RESULTS OF A SERIES OF SPANISH CASES WITH 263 PREGNANCIES IN PRIMARY PTI

Lopez, TJG; (...); Hermida, G.

Meeting Abstract. 2017

  • Open Access.

Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial

Bastidas, A; (...); ZOE-HSCT Study Grp Collaborators

Article. 10.1001/jama.2019.9053. 2019

  • Open Access.

Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment

Palanques-Pastor T; (...); Poveda Andrés JL

Article. 10.1159/000517813. 2021


Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study

Ferra, Christelle; (...); Baltasar, Patricia

Meeting Abstract. 10.1182/blood-2022-162186. 2022

  • Open Access.

Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real World Setting in Spain: The Venares Study

Baltasar, Patricia; (...); Ferra, Christelle

Meeting Abstract. 10.1182/blood-2021-147685. 2021

  • Open Access.

EFFICACY OF IBRUTINIB IN THE TREATMENT OF LINFOPROLIFERATIVE SYNDROMES: EXPERIENCE IN REAL LIFE OF THE VALENCIAN COMMUNITY

Martin, EMD; (...); Castera, MJT

Meeting Abstract. 2018

  • Open Access.

eLearning of pharmacokinetic monitoring in hemophilia with application in the clinical practice

Bonanad, S; (...); Megias-Vericat, JE

Meeting Abstract. 2018


Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.

Peffault de Latour R; (...); Risitano AM

Article. 10.1056/NEJMoa2109965. 2022

  • Open Access.

ELTROMBOPAG ADDED TO STANDARD IMMUNOSUPPRESSION IMPROVES RESPONSE RATE IN SEVERE APLASTIC ANEMIA: RESULTS OF THE MULTICENTER PHASE III PROSPECTIVE RANDOMIZED RACE TRIAL

Risitano, A. M.; (...); de latour, R. Peffault

Meeting Abstract. 2021

  • Open Access.

EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING & REIMBURSEMENT (P&R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN

Badia, F. J.; (...); Shepherd, J.

Meeting Abstract. 2019


Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with hematological malignancies.

Gudiol C; (...); de la Cámara R

Article. 10.1016/j.eimc.2019.01.013. 2020


Exploratory analysis for the implementation of antineoplastic logarithmic dose banding

Albert-Mari, A; (...); Poveda-Andres, JL

Article. 10.1007/s11096-018-0714-9. 2018


EXTENDED MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD EXTENSION STUDY

F, de Andres-Nogales; (...); Martinez, M.

Meeting Abstract. 2019


Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease

Beltran, B; (...); Nos, P

Article. 10.1159/000492626. 2019


Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report

Fernandez-Sanchez, M; (...); Poveda-Andres, JL

Article. 10.1002/bdr2.1942. 2021


Frequency, characteristics and outcomes of Lymphoproliferative Disorders After Allogeneic Stem Cell Transplant: results of a multicenter study from the Grupo Espanol de Trasplante Hematopoyetico (GETH)

Garcia Cadenas, Irene; (...); Solano, Carlos

Meeting Abstract. 2018


Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH)

Garcia-Cadenas, I; (...); Spanish Grp Blood & Marrow Tran

Article. 10.1111/ejh.13226. 2019


Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study.

de la Rubia J; (...); Bonanad, Santiago

Article. 10.1016/j.jgo.2022.10.016. 2022

  • Open Access.

Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis

Poveda Andres, Jose Luis

Editorial Material. 2022


GUIDELINES OF PRESCRIPTION IN FIRST LINE OF PATIENTS WITH MULTIPLE MYELOMA NOT CANDIDATES TO TRANSPLANTATION STRATIFIED BY AGE IN REAL LIFE IN SPAIN BETWEEN 2012 AND 2016

Cejalvo, M. J.; (...); Sarra, J.

Meeting Abstract. 2019

  • Open Access.

Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report

Company-Albir, MJ; (...); Poveda, JL

Article. 10.1111/jcpt.12568. 2017


Hazardous drugs levels in compounding area surfaces of Hospital Pharmacies Services: multicentric study

Valero-Garcia, S; (...); Spanish Hosp Pharmacy Units

Article. 10.7399/fh.10935. 2018

  • Open Access.

Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

Solana-Altabella, Antonio; (...); Martinez-Cuadron, David

Article. 10.3390/cancers14081921. 2022

  • Open Access.

High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.

El-Qutob D; (...); Carrera-Hueso FJ

Article. 10.1016/j.hrtlng.2022.02.003. 2022

  • Open Access.

High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance

Garcia-Marco, JA; (...); GELLC Study Grp

Article. 10.3324/haematol.2018.204891. 2019

  • Open Access.

High-permeability region size on perfusion CT predicts hemorrhagic transformation after intravenous thrombolysis in stroke

Puig, J; (...); Castellanos, M

Article. 10.1371/journal.pone.0188238. 2017

  • Open Access.

Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies

Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo

Article. 10.7399/fh.11729. 2022


Hospitalization budget impact during the COVID-19 pandemic in Spain.

Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.

Article. 10.1186/s13561-021-00340-0. 2021

  • Open Access.

How can artificial intelligence optimize value-based contracting?

Poveda, Jose Luis; (...); Medrano, Ignacio H.

Letter. 10.1186/s40545-022-00475-3. 2022

  • Open Access.

IBRUTINIB IN COMBINATION WITH R-GEMOX-D IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN RECALLING OR REFRACTORY: PHASE II STUDY OF THE GELTAMO GROUP

Rey, Bua Beatriz; (...); Martin, A.

Meeting Abstract. 2020

  • Open Access.

Idelalisib for Relapsed/Refractory Follicular Lymphoma: Retrospective Study from Spanish Lymphoma Group Geltamo (GELT-IDE-2018-02)

Sancho, Juan-Manuel; (...); Guillermo Armando, Lopez

Meeting Abstract. 10.1182/blood-2019-125921. 2019

  • Open Access.

Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors.

de la Asuncion Carlos, Solano; (...); Navarro, David

Letter. 10.1111/bjh.18655. 2023

  • Open Access.

Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease

Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro

Meeting Abstract. 10.1182/blood-2022-166826. 2022

  • Open Access.

IMPACT OF ALLELIC STATUS OF TP53 MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML)

Ibanez, Mariam; (...); Sanz, Guillermo

Meeting Abstract. 2020

  • Open Access.

Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.

Megías-Vericat JE; (...); Montesinos P

Article. 10.1080/10428194.2020.1839650. 2020


Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma.

Martinez, Carmen; (...); Garcia-Sanz, Ramon

Article. 10.1007/s00277-022-05011-6. 2022


Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019

Badia X; (...); Hernández C

Article. 10.1186/s13023-020-01507-4. 2020

  • Open Access.

Impact of voriconazole plasma concentrations on treatment response in critically ill patients

Ruiz, J; (...); Ramirez, P

Article. 10.1111/jcpt.12817. 2019


Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases

Edo-Solsona, MD, Vitoria-Minana, I, Poveda-Andres, JL

Article. 10.7399/fh.11262. 2020


Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.1159/000478969. 2018


INCIDENCE AND CHARACTERISTICS OF POST-TRANSPLANT ALLOGENIC LYMPHOPROLIFERATIVE SYNDROMES. EXPERIENCE OF SPANISH GROUP OF HEMATOPOIETIC TRANSPLANT (GETH)

San Segundo, LY; (...); Solano, C.

Meeting Abstract. 2017

  • Open Access.

Incidence and Management of Aplastic Anemia in Spain (IMAS). An Ambispective Study of Biodonostia / Pethema

Vallejo, C; (...); Jarque, I

Meeting Abstract. 2020


Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.

Rodríguez-Veiga R; (...); Sanz GF

Article. 10.1007/s00277-019-03744-5. 2019


Individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A

Vericat, JEM; (...); Bonanad, S

Meeting Abstract. 2018


Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study

Luisa Lozano, Maria; (...); Vicente Garcia, Vicente

Meeting Abstract. 10.1182/blood-2019-122237. 2019

  • Open Access.

Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy

Bastida, G; (...); Nos, P

Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019

  • Open Access.

Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1080/10428194.2017.1323267. 2017


Influence of pharmacokinetic/pharmacodynamic ratio on vancomycin treatment response in paediatric patients with Staphylococcus aureus bacteremia.

Ruiz J; (...); Poveda JL

Article. 10.23736/S0026-4946.18.04978-2. 2018


Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.

Megías-Vericat JE; (...); Montesinos P

Article. 10.1097/FPC.0000000000000431. 2021


Intraperitoneal vancomycin in neonates during peritoneal dialysis: A case report

Company-Albir, MJ; (...); Poveda, JL

Article. 10.1111/jcpt.12842. 2019

  • Open Access.

Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol.

Solana-Altabella A; (...); Poveda JL

Article. 10.1177/1078155220904410. 2020


Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19

Palanques-Pastor, T, Lopez-Briz, E, Andres, JLP

Article. 10.1136/ejhpharm-2020-002322. 2020

  • Open Access.

Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial

Rosinol, Laura; (...); Blade Creixenti, Joan

Meeting Abstract. 10.1182/blood-2021-146798. 2021

  • Open Access.

LENALIDOMIDE IN COMBINATION WITH R-ESHAP IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMAS (DLBCL) REFRACTORY OR IN RELAPSE: STUDY PHASE 2 OF THE GELTAMO SPANISH GROUP

Baile, M.; (...); Martin, A. A.

Meeting Abstract. 2017

  • Open Access.

Lineage switch from B lymphoblastic leukemia with KMT2A-rearranged to mixed-phenotype acute leukemia under daratumumab

Marco-Ayala, J; (...); Peris, MLS

Editorial Material. 10.5045/br.2020.2020059. 2020

  • Open Access.

Long Term Discontinuation of Eltrombopag after Remission in Primary Immune Thrombocytopenia: 8-Year Follow-up Data from 15 Spanish Centers

Jose Gonzalez-Lopez, Tomas; (...); Sanz, Miguel A.

Meeting Abstract. 10.1182/blood-2019-129274. 2019


LYFOMA POST-TRANSPLANT TYPE BURKITT: CLINICAL CHARACTERISTICS AND PRONOSTICAS IN A MULTICENTRAL STUDY

Varela, SB; (...); Bosch, F.

Meeting Abstract. 2017

  • Open Access.

Management of Adult Patients with Primary Immune Thrombocytopenia (ITP) in Clinical Practice: A Consensus Approach of the Spanish ITP Expert Group.

Mingot-Castellano ME; (...); González Porras JR

Article. 10.1155/2019/4621416. 2019

  • Open Access.

Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts

Calleja-Panero, JL; (...); Gil, A

Article. 10.17235/reed.2020.6895/2020. 2020

  • Open Access.

Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.

Megías-Vericat JE; (...); Poveda-Andrés JL

Article. 2021

  • Open Access.

Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.

Vázquez Polo A; (...); Vázquez Costa JF

Article. 10.20960/nh.03946. 2022

  • Open Access.

Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A

Bonanad, S; (...); Santos, S

Article. 10.1007/s12325-021-01853-0. 2021

  • Open Access.

Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Article. 10.3390/cancers14030596. 2022

  • Open Access.

Metyrapone as treatment in the neonatal McCune-Albright syndrome

de Mingo, Carmen; (...); Garcia-Robles, Ana

Article. 10.1515/jpem-2020-0036. 2020


Monitoring coagulation factors during surgery. A systematic review

Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11766. 2021


Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).

Valero-García S; (...); Delgado-Sánchez O

Article. 10.7399/fh.11655. 2021

  • Open Access.

Monitoring the quality of the hospital pharmacoterapeutic process by sentinel patient program.

Fernandez-Megia, MJ; (...); Poveda Andrés JL

Article. 10.7399/fh.10793. 2018

  • Open Access.

Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments

Gomez-Cebrian, N; (...); Pineda-Lucena, A

Review. 10.3390/cancers13184544. 2021

  • Open Access.

National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)

Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel

Correction. 10.7399/fh.11740. 2021

  • Open Access.

National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies

Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis

Meeting Abstract. 10.1182/blood-2022-169938. 2022

  • Open Access.

Nivolumab for Heavily Pretreated Relapsed/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation, GELTAMO)

Martinez, C; (...); Garcia-Sanz, R

Meeting Abstract. 10.1182/blood-2018-99-115774. 2018

  • Open Access.

Non-traumatic spontaneous abdominal haemorrhage

Ballesta, M.; (...); Lerga, P. Estelles

Article. 10.1016/j.rx.2022.11.003. 2023


Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus

Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis

Article. 10.1097/MD.0000000000032208. 2022

  • Open Access.

Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Kim, Won-Seog; (...); Walewski, Jan

Meeting Abstract. 10.1182/blood-2022-158406. 2022

  • Open Access.

ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.

Poveda JL; (...); Badia X

Article. 10.1186/s13023-022-02610-4. 2023

  • Open Access.

Ofatumumab as Part of Reduced Intensity Conditioning in High Risk b-cell Lymphoma Patients: Results from a Prospective Multicenter Phase-II Trial

Cabrero, M; (...); Caballero, D

Meeting Abstract. 2020


Online course of pharmacokinetic monitoring in hemophilia with application in the clinical practice

Bonanad, S; (...); Poveda, JL

Meeting Abstract. 2018


Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients

Ibanez, Mariam; (...); Luna I

Article. 10.3390/diagnostics12040953. 2022

  • Open Access.

Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol

Garcia-Robles, Ana; (...); Carrascosa, MA

Article. 10.3389/fped.2020.00372. 2020

  • Open Access.

Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Correction. 10.3389/fped.2021.834454. 2022

  • Open Access.

Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia.

Sanz J; (...); Piñana JL

Article. 10.1016/j.bbmt.2019.08.020. 2020

  • Open Access.

Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project

Morillo-Verdugo, R; (...); Diaz-Olmo, J

Article. 10.7399/fh.11719. 2021


Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.

Morillo-Verdugo R; (...); Díaz-Olmo J

Article. 2021

  • Open Access.

Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy

Margusino-Framiñán L; (...); Morillo-Verdugo R

Article. 10.7399/fh.11498. 2020

  • Open Access.

Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia

Megias-Vericat, JE; (...); Montesinos, P

Review. 10.2174/1389200218666171101124931. 2018


Pharmacometabolomics by NMR in Oncology: A Systematic Review.

Gómez-Cebrián N; (...); Pineda-Lucena A

Article. 10.3390/ph14101015. 2021

  • Open Access.

Pharmacotherapeutic management of advanced therapy medicinal products

Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia

Article. 10.7399/fh.13036. 2022


Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia

Robak, T; (...); Jolles, S

Article. 10.1182/bloodadvances.2020002003. 2020

  • Open Access.

Pilot evaluation of home delivery programme in haemophilia

Megias-Vericat, JE; (...); Poveda-Andres, JL

Article. 10.1111/jcpt.12718. 2018


PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS

Vericat, JEM; (...); Iorio, A

Meeting Abstract. 2020


Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.

Romero S; (...); Sanz J

Article. 10.1080/10428194.2018.1474462. 2019


Posttransplant monomorphic Burkitt's lymphoma: clinical characteristics and outcome of a multicenter series

Bobillo, S; (...); Grp Espanol Linfomas Trasplante

Article. 10.1007/s00277-018-3473-8. 2018

  • Open Access.

Potential survival benefit for patients receiving allogeneic hematopoietic stem cell transplantation after nivolumab therapy for relapse/refractory Hodgkin lymphoma: Real-life experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation, GELTAMO).

Martínez C; (...); García-Sanz R

Article. 10.1016/j.bbmt.2020.02.003. 2020

  • Open Access.

Practical guide to emergency treatment of thrombotic microangiopathy

Romero S; (...); Grupo de Microangiopatía Trombótica del Hospital Universitario y Politécnico La

Editorial Material. 10.1016/j.medcli.2018.01.013. 2018


Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process

Valero, S; (...); Poveda, JL

Article. 10.1016/j.yrtph.2018.03.001. 2018


Predicting Malignant and Paramalignant Pleural Effusions by Combining Clinical, Radiological and Pleural Fluid Analytical Parameters

Herrera Lara S; (...); Morales Suárez-Varela M

Article. 10.1007/s00408-017-0032-3. 2017


Predictive Factors for Thrombopoietin Receptor Agonist Free Responses in Chronic ITP Patients: A Multicenter Retrospective Study with Long-Term Follow-up

Luisa Lozano, Maria; (...); Vicente Garcia, Vicente

Meeting Abstract. 10.1182/blood-2019-125580. 2019

  • Open Access.

PREDICTORS OF TREATMENT FREE RESPONSES WITH THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH PTI

Lozano Almela, M. L.; (...); Vicente, V.

Meeting Abstract. 2019

  • Open Access.

PRELIMINAR STUDY OF THERAPY ADHERENCE CONTROLLED BY PRESCRIPTION OF MEDICATION AND SELF-PERCEPTION ADHERENCE OF INFLAMMATORY CHRONIC DISEASE PATIENTS

Garcia, EG; (...); Ivorra, JAR

Meeting Abstract. 10.1136/annrheumdis-2019-eular.5937. 2019

  • Open Access.

Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)

Abrisqueta, Pau; (...); Bosch, Francesc

Meeting Abstract. 10.1182/blood-2019-128470. 2019


Preparación y administración de perfusiones de insulina en neonatología: Encuesta nacional.

García-Robles A; (...); Aguar-Carrascosa M

Letter. 10.1016/j.anpedi.2020.06.008. 2021

  • Open Access.

Preparation and administration of insulin infusions in neonatology: A national survey.

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Article. 10.1016/j.anpede.2020.06.015. 2021

  • Open Access.

Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry

Villegas, A; (...); Urbano, A

Article. 10.1007/s00277-017-3059-x. 2017


Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review

Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11780. 2021

  • Open Access.

Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.

Tamariz-Amador, Luis-Esteban; (...); Troconiz, Inaki F.

Article. 10.1016/j.clml.2022.04.024. 2022

  • Open Access.

Progression-free survival at 2years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma

Jimenez-Ubieto, A; (...); GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) cooperative stu

Article. 10.1002/cam4.1217. 2017

  • Open Access.

Quantification of physical activity in adult patients with haemophilic arthropathy in prophylaxis treatment using a fitness tracker

Perez-Alenda, S; (...); Querol, F

Letter. 10.1111/hae.13388. 2018


Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).

Abrisqueta, Pau; (...); Villanueva, Miguel

Article. 10.1016/j.clml.2021.07.022. 2021

  • Open Access.

Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease

Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro

Meeting Abstract. 10.1182/blood-2022-167247. 2022

  • Open Access.

Relevancia de la anfotericina B liposomal en el tratamiento de las infecciones fúngicas invasoras en pacientes oncohematológicos.

García-Vidal C, Vázquez L, Jarque I

Article. 10.1016/j.riam.2021.03.001. 2021

  • Open Access.

RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group.

Bastos-Oreiro M; (...); López-Guillermo A

Article. 10.1007/s00277-020-03918-6. 2020


Results of the Ebmt Saawp Phase III Prospective Randomized Multicenter Race Study of Horse Atg and Ciclosporin with or Without Eltrombopag in Naive Saa Patients

de Latour, RP; (...); Risitano, A

Meeting Abstract. 2020


RESULTS OF THE PEGASUS PHASE III TRIAL FOR THE COMPARISON OF PEGCETACOPLAN WITH ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

Jarque, Isidro; (...); Peffault, de latour Regis

Meeting Abstract. 2020

  • Open Access.

RETROSPECTIVE CONTROL CASE STUDY ON THE EFFICACY OF AUTOLOGOUS TRANSPLANTATION OF HAEMATOPOIETIC PROGENITORS IN THE FIRST LINE TREATMENT OF PATIENTS WITH PERIPHERAL T CELL LYMPHOMA

Parra, ML; (...); Martin, A. A.

Meeting Abstract. 2017

  • Open Access.

Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia

Robak, Tadeusz; (...); Jolles, Stephen

Meeting Abstract. 10.1182/blood-2019-129839. 2019

  • Open Access.

Safety and efficacy of the BCR inhibitors after allogeneic stem cell transplantation for CLL

Yanez, L; (...); Bosch, F

Meeting Abstract. 2019


Salvage therapy with topical posaconazole in lung transplant recipients with invasive Scedosporium infection.

Sole, A; (...); Peman, J

Article. 10.1111/ajt.14580. 2018

  • Open Access.

Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry

Jimenez-Ubieto, A; (...); Lahuerta, JJ

Letter. 10.1038/s41409-018-0096-6. 2018


SEFH National Survey-2019: general characteristics, staffing, material resources and information systems in Spain's hospital pharmacy departments.

Pérez-Encinas M; (...); Calleja-Hernández MÁ

Article. 10.7399/fh.11565. 2020

  • Open Access.

Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study

Stefania Infante, Maria; (...); Grande, Carlos

Article. 10.1002/cam4.4293. 2021

  • Open Access.

SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization

Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis

Article. 10.1111/jcpt.13703. 2022

  • Open Access.

STUDY OF CHRONIC ANEMIA IN THE ELDERLY

Villalba, A.; (...); Sanz, M. A.

Meeting Abstract. 2017

  • Open Access.

Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia

Megías-Vericat JE; (...); Montesinos P

Review. 10.3390/pharmaceutics14040878. 2022

  • Open Access.

The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity

Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar

Article. 10.1007/s00431-022-04628-z. 2022


The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.

Gil-Nagel A; (...); Gil A

Article. 10.1016/j.yebeh.2022.108711. 2022

  • Open Access.

The International Network for Evaluating Outcomes (iNeo) of neonates: evolution, progress and opportunities

Shah, Prakesh S.; (...); Int Network Evaluating Outcomes iN

Review. 10.21037/tp.2019.07.06. 2019

  • Open Access.

THE LASTING RESPONSE OF ELTROMBOPAG IN PRIMARY PTI IS A PREDICTOR FOR THE PROBABILITY OF DISCONTINUING THE SUCCESS OF ELTROMBOPAG

Porras, JRG; (...); Bastida, J. M.

Meeting Abstract. 2017

  • Open Access.

The view of experts on initiatives to be undertaken to promote equity in the access to orphan drugs and specialised care for rare diseases in Spain: A Delphi consensus

Torrent-Farnell, J; (...); Lizan, L

Article. 10.1016/j.healthpol.2018.03.002. 2018


THROMBOTIC EVENTS IN PATIENTS WITH PTI TREATED WITH THROMBOPOIETIN RECEPTOR AGONISTS. IDENTIFICATION OF PREDISPOSING FACTORS

Lozano Almela, M. L.; (...); Vicente, V.

Meeting Abstract. 2019

  • Open Access.

Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule.

Marques MR; (...); Mangas-Sanjuan V

Article. 10.1111/apa.14944. 2020


Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy

Del Rio-Bermudez, C; (...); Poveda, JL

Editorial Material. 10.1186/s40545-020-00276-6. 2020

  • Open Access.

Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma

Cejalvo, MJ; (...); de la Rubia, J

Article. 10.1007/s00277-021-04529-5. 2021


Undetectable levels of adalimumab in clinical practice: Should we say goodbye to the drug?

Bejar, S; (...); Mateu, PN

Meeting Abstract. 2020


Updated Results of a Phase 2 Study from GELTAMO Investigating the Combination of Ibrutinib with R-GEMOX in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Bua, BR; (...); Garcia-Sancho, AM

Meeting Abstract. 2021


Use and handling safety of Mini-Spike 2 (R) chemo and puresite for safe chemotherapy compounding in a hospital pharmacy

Garcia, SV; (...); Andres, JLP

Article. 10.1016/j.yrtph.2018.10.002. 2018


USE OF CAPLACIZUMAB IN THE ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA

Dominguez Hernandez, L.; (...); Gomez Segui, I

Meeting Abstract. 2019

  • Open Access.

Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia.

González-López TJ; (...); García-Frade LJ

Article. 10.1111/ejh.13370. 2020

  • Open Access.

Validation of a multivariable prediction model for post-engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients

Rodriguez-Veiga, Rebeca; (...); Sanz, Miguel A.

Article. 10.1111/myc.12891. 2019


VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study

Dachs, LR; (...); Blade, J

Meeting Abstract. 10.1182/blood-2018-99-111924. 2018

  • Open Access.

Campos de estudio

Compartir